Filtered By:
Specialty: Hematology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 1625 results found since Jan 2013.

Left atrial size and risk of stroke in patients in sinus rhythm. A systematic review.
Abstract Little is known about the risk of stroke associated with left atrial enlargement in patients in sinus rhythm, and whether such patients may have an unmet need for thromboprophylaxis. In this systematic review we summarise the existing evidence concerning left atrial size and risk of stroke in patients in sinus rhythm. Nine cohort studies were identified, analysing a total of 67,875 participants and 3,093 stroke outcomes. Rates of stroke per 100 person-years in patients with left atrial enlargement and in sinus rhythm ranged from 0.59 in a population-based cohort to 2.07 in patients with hypertension. All ...
Source: Thrombosis and Haemostasis - April 13, 2016 Category: Hematology Authors: Overvad TF, Brønnum Nielsen P, Larsen TB, Søgaard P Tags: Thromb Haemost Source Type: research

Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation.
Abstract In patients with acute stroke and atrial fibrillation (AF), the risk of early recurrence has been reported to range between 0.1 % and 1.3 % per day. Anticoagulants are the most effective therapy for the prevention of recurrent ischaemic stroke in these patients, but randomised clinical trials have failed to produce any evidence supporting the administration of heparin within 48 hours from stroke onset as it has been associated with a non-significant reduction in the recurrence of ischaemic stroke, no substantial reduction in death and disability, and an increase in intracranial bleeding. As early haem...
Source: Thrombosis and Haemostasis - June 22, 2016 Category: Hematology Authors: Paciaroni M, Agnelli G, Ageno W, Caso V Tags: Thromb Haemost Source Type: research

Associations of coagulation factors IX and XI levels with incident coronary heart disease and ischemic stroke: the REGARDS study.
CONCLUSIONS: Higher FIX antigen was associated with incident CHD in blacks but not whites. FIX levels may increase CHD risk among blacks. This article is protected by copyright. All rights reserved. PMID: 28393470 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 10, 2017 Category: Hematology Authors: Olson NC, Cushman M, Judd SE, Kissela BM, Safford MM, Howard G, Zakai NA Tags: J Thromb Haemost Source Type: research

CHA 2 DS 2 –VASc score predicts short- and long-term outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis
AbstractThe CHA2DS2–VASc score is a validated tool to assess the thromboembolic risk in patients with atrial fibrillation. Pre-stroke CHA2DS2–VASc score may predict outcome in patients with acute ischemic stroke (AIS) without atrial fibrillation. The aim of this study was to investigate if the pre-stroke CHA2DS2–VASc score is able to predict short- and long-term outcomes in AIS patients treated with intravenous thrombolysis (IVT). The study group consisted of 256 consecutive patients admitted to the Udine University Hospital with AIS and underwent IVT between January 2015 to March 2017. The pre-stroke CH A2DS2–VASc...
Source: Journal of Thrombosis and Thrombolysis - October 24, 2017 Category: Hematology Source Type: research

Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
This article provides an update on three randomized controlled trials of rivaroxaban, a direct, oral factor Xa inhibitor, that are complete or are ongoing, in these unmet areas of stroke prevention: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention (PIONEER AF-PCI) trial; the New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE E...
Source: Thrombosis and Haemostasis - March 22, 2018 Category: Hematology Authors: Gibson CM, Hankey GJ, Nafee T, Welsh RC Tags: Thromb Haemost Source Type: research

Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution.
Abstract Stroke prevention is a key clinical concern in the management of patients with atrial fibrillation. Oral anticoagulation treatment reduces the risk of disabling stroke, but the treatment increases the risk of bleeding. For decades, the decision to initiate oral anticoagulation has been guided by clinical risk scoring systems such as the CHADS2 and CHA2DS2-VASc scores. In this narrative review, we focus on the recent discussion of the "Sc" (Sex Category) criterion in the CHA2DS2-VASc score. Epidemiological considerations when assessing stroke rates in cohorts are discussed, and the implications of differen...
Source: Thrombosis and Haemostasis - April 20, 2020 Category: Hematology Authors: Nielsen PB, Overvad TF Tags: Thromb Haemost Source Type: research

Stroke and left atrial thrombi after cryoballoon ablation of atrial fibrillation: incidence and predictors. Results from a long-term follow-up
AbstractStroke after catheter ablation (CA) of atrial fibrillation (AF) is a potential complication with long term consequences. Aim of this study was to determine incidence and potential predictors of stroke and left atrial appendage (LAA) thrombi after AF ablation with cryo-energy. Two hundred nine consecutive patients with symptomatic drug refractory AF (65% male; 61  ± 11 yo, 69% paroxysmal AF, mean CHA2DS2-VASc score 2  ± 1.4) were enrolled between October 2012 until December 2015. Long term follow-up was performed with outpatient clinic visits at 6-month intervals. Incidence of stroke after CA was 1.4% (3/2...
Source: Journal of Thrombosis and Thrombolysis - May 22, 2020 Category: Hematology Source Type: research

Adverse consequences of immediate thrombolysis-related complications: a multi-centre registry-based cohort study of acute stroke
In conclusion, the risk of nosocomial infections, worsening of stroke severity, longer HASU stay, disability and death is increased following immediate TRC. The management of patients following immediate TRC is more complex than previously thought and such complexity needs to be considere d when planning an increased thrombolysis service.
Source: Journal of Thrombosis and Thrombolysis - July 13, 2021 Category: Hematology Source Type: research

Brothers in arms: platelets and neutrophils in ischemic stroke
Purpose of review In this review, we will describe how the combined ability of platelets and neutrophils to interact with each other drives ischemic stroke brain injury. Recent findings Neutrophils are one of the first cells to respond during ischemic stroke. Although animals stroke models have indicated targeting neutrophils improves outcomes, clinical trials have failed to yield successful strategies. Platelets play a critical role in recruiting neutrophils to sites of injury by acting as a bridge to the injured endothelium. After initial platelet adhesion, neutrophils can rapidly bind platelets through P-sele...
Source: Current Opinion in Hematology - August 6, 2021 Category: Hematology Tags: HEMOSTASIS AND THROMBOSIS: Edited by Paul F. Bray Source Type: research

Immunity in Stroke: The Next Frontier
Thromb Haemost. 2022 Jun 10. doi: 10.1055/s-0042-1748890. Online ahead of print.ABSTRACTTranslational stroke research has long been focusing on neuroprotective strategies to prevent secondary tissue injury and promote recovery after acute ischemic brain injury. The inflammatory response to stroke has more recently emerged as a key pathophysiological pathway contributing to stroke outcome. It is now accepted that the inflammatory response is functionally involved in all phases of the ischemic stroke pathophysiology. The immune response is therefore considered a breakthrough target for ischemic stroke treatment. On one side,...
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Ting Li Arthur Liesz Source Type: research

Essen Stroke Risk Score Predicts Clinical Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Evidence From the TOPCAT trial
This study sought to determine whether the Essen Stroke Risk Score (ESRS) could predict the risks of adjudicated clinical outcomes in patients with Heart failure with preserved ejection fraction (HFpEF) from the TOPCAT trial. Of 3,441 HFpEF patients with a mean follow-up of 3.3 years, the risk of stroke ranged from 0.32% per year at an ESRS of 1-2 points to 1.71% per year at a score of ≥6 points. Each point increase in ESRS was associated with increased risks of stroke (HR=1.33 [95% CI 1.16-1.53]) with a C-index of 0.68, as well as myocardial infarction (HR=1.60 [95% CI 1.40-1.83]; C-index, 0.75), HF hospitalization (HR=...
Source: Thrombosis and Haemostasis - August 29, 2022 Category: Hematology Authors: Wengen Zhu Yalin Cao Min Ye Hulin Huang Yuzhong Wu Jianyong Ma Yugang Dong Xiao Liu Chen Liu Gregory Yh Lip Source Type: research

Cancer and stroke: What do we know and where do we go?
Cancer is an increasingly recognized cause for ischemic stroke, with recent acknowledgement of cancer-related stroke as an emerging stroke subtype with unique pathophysiologic mechanisms. In addition, cancer-related stroke may differ from stroke in the general population as cancer patients may not receive guideline-recommended stroke care, and the occurrence of stroke may also preclude patients from receiving optimal cancer treatments. Due to the high degree of morbidity and mortality associated with both conditions, understanding the relationship between stroke and cancer is crucial.
Source: Thrombosis Research - September 16, 2022 Category: Hematology Authors: Ronda Lun, Deborah Siegal, Tim Ramsay, Dar Dowlatshahi Source Type: research

The thrombus proteome in stroke reveals a key role of the innate immune system and new insights associated with its aetiology, severity and prognosis
CONCLUSIONS: The use of the SWATH-MS in thrombi from IS patients has provided new insights of pathways and players involved in its aetiology, severity and prognosis. The prominent role of the innate immune system identified might pave the way for the development of new biomarkers and therapeutic approaches in this disease.PMID:37100394 | DOI:10.1016/j.jtha.2023.04.015
Source: Thrombosis and Haemostasis - April 26, 2023 Category: Hematology Authors: Chary Lopez-Pedrera Rafael Oteros Alejandro Ib áñez-Costa Mar ía Luque-Tévar Laura Mu ñoz-Barrera Nuria Barbarroja Eduardo Chicano-G álvez Juan Marta-Enguita Josune Orbe Francisco Velasco Carlos Perez-S ánchez Source Type: research